EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Human Colitis‐on‐Chip Model Reveals Dual Roles of Butyrate in Epithelial and Macrophage Defense Against Candida albicans Tissue Invasion

Manuel Allwang, Maximilian Wipplinger, Parastoo Akbarimoghaddam, Raquel Alonso-Roman, Zoltan Cseresnyes, Axel Dietschmann, Valentin Wegner, Adrian Feile, Yann Bachelot, Maria Warschinke, Mohamed I Abdelwahab Hassan, Sonnhild Mittag und 5 weitere

Small · 2026-07 · 22 (37)

DOI: 10.1002/smll.202600074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 15.05.2026. Verfasst von Manuel Allwang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry II, Jena University Hospital, Jena, Germany. Hauptthemen laut MEDLINE: Candida albicans, Butyrates, Macrophages, Colitis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, Exploration Grant of the Boehringer Ingelheim Foundation (BIS), Free State of Thuringia and co-funded by the European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microbial dysbiosis in inflammatory bowel disease (IBD) reduces intestinal butyrate levels, compromising epithelial barrier integrity and enabling overgrowth of opportunistic pathogens such as Candida albicans . Here, we present a human immunocompetent colitis‐on‐chip model (CooC) that mimics key features of inflamed gut mucosa, including DSS‐induced epithelial damage and C. albicans tissue invasion. Using this model, we uncover dual protective roles of microbiota‐derived butyrate: (i) stabilization of epithelial adherens junctions and promotion of epithelial renewal, thereby restricting fungal invasion; and (ii) modulation of macrophage function to enhance antifungal activity while attenuating inflammasome‐mediated inflammation. Butyrate pretreatment preserves barrier function, limits fungal translocation, and promotes macrophage viability through the inhibition of histone deacetylase (HDAC) and the suppression of NLRP3 inflammasome activation. These findings position butyrate as a key metabolite in orchestrating epithelial‐immune defense against fungal exacerbation in colitis, supporting its therapeutic and preventive potential in restoring mucosal resilience in IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Candida albicansButyratesMacrophagesColitisEpithelial CellsHumansMicrophysiological SystemsIntestinal Barrier FunctionIntestinal Mucosa

Stichwörter der Autor:innen

IBDinfectioninflammationmicrobiomeshort‐chain fatty acids

Substanzen

Butyrates

Autor:innen und Institutionen

  • Institute of Biochemistry II, Jena University Hospital, Jena, Germany.
  • Cluster of Excellence Balance of the Microverse, Friedrich Schiller University, Jena, Germany.
  • Applied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute (HKI), Jena, Germany.
  • Faculty of Biological Sciences, Friedrich Schiller University, Jena, Germany.
  • Junior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute (HKI), Jena, Germany.
  • Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute (HKI), Jena, Germany.

ORCID-Profile: Alexander S Mosig

Förderung

  • German Research Foundation
  • Exploration Grant of the Boehringer Ingelheim Foundation (BIS)
  • Free State of Thuringia and co-funded by the European Union
  • DFG Cluster of Excellence "Balance of the Microverse"
  • Collaborative Research Center "PolyTarget"
  • Scholarship from the Interdisciplinary Center of Clinical Research of the Jena University Hospital
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Allwang, M., Wipplinger, M., Akbarimoghaddam, P., Alonso-Roman, R., Cseresnyes, Z., Dietschmann, A., Wegner, V., Feile, A., Bachelot, Y., Warschinke, M., Hassan, M. I. A., Mittag, S., Huber, O., Hube, B., Gresnigt, M. S., Figge, M. T., & Mosig, A. S. (2026). Human Colitis‐on‐Chip Model Reveals Dual Roles of Butyrate in Epithelial and Macrophage Defense Against Candida albicans Tissue Invasion. Small, 22(37). https://doi.org/10.1002/smll.202600074

Vancouver

Allwang M, Wipplinger M, Akbarimoghaddam P, Alonso-Roman R, Cseresnyes Z, Dietschmann A, et al. Human Colitis‐on‐Chip Model Reveals Dual Roles of Butyrate in Epithelial and Macrophage Defense Against Candida albicans Tissue Invasion. Small. 2026;22(37). doi:10.1002/smll.202600074

BibTeX
@article{Allwang2026,
  author = {Allwang, Manuel and Wipplinger, Maximilian and Akbarimoghaddam, Parastoo and Alonso-Roman, Raquel and Cseresnyes, Zoltan and Dietschmann, Axel and Wegner, Valentin and Feile, Adrian and Bachelot, Yann and Warschinke, Maria and Hassan, Mohamed I Abdelwahab and Mittag, Sonnhild and Huber, Otmar and Hube, Bernhard and Gresnigt, Mark S and Figge, Marc Thilo and Mosig, Alexander S},
  title = {Human Colitis‐on‐Chip Model Reveals Dual Roles of Butyrate in Epithelial and Macrophage Defense Against Candida albicans Tissue Invasion},
  journal = {Small},
  year = {2026},
  volume = {22},
  number = {37},
  doi = {10.1002/smll.202600074}
}
Kostenlos starten →